Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;202(3):539-549.
doi: 10.1111/bjh.18877. Epub 2023 May 28.

Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy

Shuai-Shuai Ge #  1   2 , Qiao-Cheng Qiu #  1   2 , Hai-Ping Dai #  1   2 , Xiang-Dong Shen #  1   2 , Tian-Mei Wu  3 , Jia-Hui Du  4 , Chao-Ling Wan  1   2 , Hong-Jie Shen  1   2 , De-Pei Wu #  1   2 , Sheng-Li Xue #  1   2 , Song-Bai Liu #  4
Affiliations

Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy

Shuai-Shuai Ge et al. Br J Haematol. 2023 Aug.

Abstract

Fms-like tyrosine kinase 3 (FLT3) is frequently mutated in haematological malignancies. Although canonical FLT3 mutations including internal tandem duplications (ITDs) and tyrosine kinase domains (TKDs) have been extensively studied, little is known about the clinical significance of non-canonical FLT3 mutations. Here, we first profiled the spectrum of FLT3 mutations in 869 consecutively newly diagnosed acute myeloid leukaemia (AML), myelodysplastic syndrome and acute lymphoblastic leukaemia patients. Our results showed four types of non-canonical FLT3 mutations depending on the affected protein structure: namely non-canonical point mutations (NCPMs) (19.2%), deletion (0.7%), frameshift (0.8%) and ITD outside the juxtamembrane domain (JMD) and TKD1 regions (0.5%). Furthermore, we found that the survival of patients with high-frequency (>1%) FLT3-NCPM in AML was comparable to those with canonical TKD. In vitro studies using seven representative FLT3-deletion or frameshift mutant constructs showed that the deletion mutants of TKD1 and the FLT3-ITD mutant of TKD2 had significantly higher kinase activity than wild-type FLT3, whereas the deletion mutants of JMD had phosphorylation levels comparable with wild-type FLT3. All tested deletion mutations and ITD were sensitive to AC220 and sorafenib. Collectively, these data enrich our understanding of FLT3 non-canonical mutations in haematological malignancies. Our results may also facilitate prognostic stratification and targeted therapy of AML with FLT3 non-canonical mutations.

Keywords: FLT3; FLT3 inhibitor; haematological malignancy; kinase activity; mutation spectrum.

PubMed Disclaimer

References

REFERENCES

    1. Ley TJ. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia (vol 368, pg 2059, 2013). N Engl J Med. 2013;369(1):98.
    1. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-21.
    1. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650.
    1. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47.
    1. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97(8):2434-9.

Publication types

Substances

LinkOut - more resources